European Medicines Agency issues positive opinion for Eli Lilly's Jaypirca for leukemia treatment.

From Nasdaq: 2025-02-28 08:38:43

The European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion for Eli Lilly and Company’s Jaypirca, a non-covalent Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia. The decision by the European Commission is expected in the next one to two months. Jaypirca also has conditional marketing authorization for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor. Stay updated on health news at rttnews.com.



Read more at Nasdaq: Eli Lilly: CHMP Issues Positive Opinion For Jaypirca – Quick Facts